References
- Gründker C, Günthert A R, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone (GnRH) system in gynecological cancers. Eur J Endocrinol 2002; 146: 1–14
- Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz K D, Schally A V. High affinity binding and direct antiproliferative effects of LHRH analogs in human ovarian cancer cell lines. Cancer Res 1993; 54: 5439–5446
- Emons G, Schröder B, Ortmann O, Westphalen S, Schulz K D, Schally A V. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77: 1458–1464
- Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar S S, Neill J D, Schulz K D, Emons G. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995; 55: 817–822
- Emons G, Ortmann O, Schulz K D, Schally A V. Growth inhibitory actions of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab 1997; 8: 355–362
- Gründker C, Völker P, Schulz K D, Emons G. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibits EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 2000; 78: 194–202
- Gründker C, Völker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein αi-mediated activation of phosphotyrosine phosphatase. Endocrinology 2003; 142: 2369–2380
- Emons G, Müller V, Ortmann O, Grossmann G, Trautner U, Stuckrad B V, Schulz K D, Schally A V. Luteinizing hormone-releasing hormone agonist triptorelin antagonises signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 1996; 9: 1129–1137
- Gründker C, Schulz K, Günthert A R, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2000; 85: 3815–3820
- Günthert A R, Gründker C, Böttcher B, Emons G. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells. Anticancer Res 2004; 24: 1727–1732
- Günthert A R, Gründker C, Hollmann K, Emons G. Luteinizing hormone-releasing hormone (LHRH) induces JunD–DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 2002; 294: 11–15
- Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G. Antiproliferative effects of the GnRH antagonists cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004; 151: 141–149
- Nicoletti I, Migliorati M, Pagliacci M C, Grignani F, Riccardi C A. Rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271–279
- Sugiyama M, Imai A, Furui T, Tamaya T. Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells. Oncol Rep 2005; 13: 813–817
- Emons G, Weiß S, Ortmann O, Gründker C, Schulz K D. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 2000; 142: 665–670